Purchase Order W81K0221P0136
Award Date 10/1/21
Potential Completion Date 9/30/25
Potential Value $277K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
LEWIS MCCHORD, WA 98431, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm-fixed-price purchase order awarded by the Defense Health Agency to Roche Diagnostics Corporation, doing business as Roche Diagnostics Corp, a manufacturer of in vitro diagnostics, reagents, and laboratory equipment. The contract, valued at $1,008,529.39, is for a cost-per-stain lease of an immunohistochemistry (IHC) staining platform to support the Department of Pathology at Madigan Army Medical Center in Tacoma, Washington. This is a new 5-year contract, with a base period...
- The Defense Health Agency awarded a $1.62 million firm fixed price BPA call to Roche Diagnostics Corporation on June 30, 2025, for a six-month slide staining reagent rental. The contract, which extends through June 30, 2025, will be performed in Bethesda, Maryland. This award was issued without a set-aside designation and represents a child contract under a larger vehicle, leveraging pre-negotiated terms and pricing established through the Defense Health Agency's procurement processes. Roche...
- This federal contract award is for the delivery of required medical reagents to the Department of the Army Medical Command. The contract was awarded to Roche Diagnostics Corporation, doing business as Roche Diagnostics Corp, a foreign-owned, for-profit manufacturer of in vitro diagnostics, reagents, laboratory instruments, and associated products and services. The contract has a potential value of $2,985,329.42 and is a Firm Fixed Price Delivery Order with no set-aside designation. Roche...
- This firm fixed-price purchase order contract was awarded by the Defense Health Agency to Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostics, laboratory instruments, and medical products. The $262,962.36 contract is for the supply of reagents and consumables to support the government-owned Roche b221 blood gas analyzers at Madigan Army Medical Center, Joint Base Lewis-McChord in Washington. The contract has a period of performance through September 30, 2025. This...
- Roche Diagnostics Corporation has been awarded a $71,916.30 delivery order contract by the Defense Health Agency to supply blood gas reagents, supplies, maintenance, and training services for Madigan Army Medical Center in Tacoma, Washington. This is a firm fixed price contract with no set-aside designation, with performance extending through September 30, 2026. As a child contract vehicle, this delivery order likely falls under one of Roche's existing Indefinite Delivery/Indefinite Quantity...
- The Defense Health Agency awarded a $6.1 million firm fixed-price purchase order to Roche Diagnostics Corporation on October 1, 2021, for advanced histology staining services including immunohistochemistry, in-situ hybridization, and immunofluorescence testing. The contract supports Brooke Army Medical Center at Joint Base San Antonio Fort Sam Houston in Texas and operates on a cost-per-test model with an ultimate completion date of September 30, 2026. No set-aside designation was used in this...
- The Defense Health Agency has awarded a purchase order to Roche Diagnostics Corporation for H and E stainer and reagents machinery with a ceiling value of $69,865.08. This firm fixed-price contract, awarded on October 1, 2025, will be performed at Fort Moore, Georgia and is scheduled for completion by September 30, 2026. The award was made without a set-aside designation, indicating open competition. Roche Diagnostics Corporation, a foreign-owned manufacturer headquartered in Indianapolis,...
- The Defense Health Agency awarded a $354,964.92 firm fixed-price delivery order to Roche Diagnostics Corporation for Roche Ventana Medical System platforms, including reagents and associated instrumentation. The delivery order, which carries no set-aside designation, was awarded on October 1, 2025, with an ultimate completion date of September 30, 2026. Performance will take place at the contractor's facility in Castleton, Indiana. Roche Diagnostics Corporation, a foreign-owned manufacturer...
- Roche Diagnostics Corporation received a firm fixed-price delivery order award from the Defense Health Agency on October 1, 2023, for reagents valued at $341,575.26, with performance at Fort Leonard Wood, Missouri, concluding March 31, 2025. This delivery order was issued without a set-aside designation and is a child contract under the GSA Schedule Critical Analyzers, Laboratory (FSS-66-III), reflecting open competition in the federal marketplace. Roche Diagnostics Corporation, headquartered in...
- This is a federal contract award to Roche Diagnostics Corporation, a leading manufacturer and distributor of in vitro diagnostics, reagents, laboratory instruments, and associated medical products and services. The contract, valued at $947,520.62, was awarded by the Medical Command within the U.S. Department of Defense on October 1, 2020 for a period ending on September 30, 2021. The contract is a Delivery Order under a Firm Fixed Price pricing type and does not have a set-aside designation....